Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data
Shares of Regulus Therapeutics ( RGLS, Financials) fell 24% to $0.89 as of 12:39 p.m. GMT-5 on Wednesday following the ...
Regulus Therapeutics stock hits 52-week low at $1.16
Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price ...
American Association of Individual Investors6d
Why Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 23.00%
Regulus Therapeutics Inc.’s RGLS share price has surged by 23.00%, which has investors questioning if this is right time to ...
Live Science3d
Snow Moon 2025: How to see February's full moon rise with the 'Heart of the Lion' before Valentine's Day
February's full Snow Moon will have a royal companion as it rises alongside Regulus, a star nicknamed "Heart of the Lion", ...
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...
American Association of Individual Investors11d
Why Regulus Therapeutics Inc.’s (RGLS) Stock Is Down 17.09%
Regulus Therapeutics Inc.’s RGLS share price has dipped by 17.09%, which has investors questioning if this is right time to ...
Regulus reports progress in ADPKD trial and FDA talks
SAN DIEGO - Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company currently trading at $1.17 per share, today announced significant clinical and regulatory advancements in its ...
Regulus announces clinical and regulatory updates from its ADPKD program
Therapeutics announced positive clinical and regulatory updates from its ADPKD program. The update includes positive topline ...
February’s Night Sky: See The Planet Parade, A ‘False Dusk’ And A ‘Ramadan Moon’
Exciting February sky events include Venus at its brightest and closest to Earth, the moon occulting the Pleiades, and a ...